SCIENTIFIC ARTICLE

Identification of Lysosome-Associated Protein Transmembrane-4 as a Novel Therapeutic Target for Osteosarcoma Treatment

Zhe-xiang Wang¹, Meng-yang Guo¹, Jing Ren², Gui-shi Li³, Xu-guo Sun¹

¹School of Medical Laboratory, Tianjin Medical University and ²Precision Medicine Center, Tianjin Medical University General Hospital, Tianjin and ³Department of Joint Orthopaedics, Yantai Yuhuangding Hospital, Yantai, China

Objective: The aim of the study is to evaluate the expression of lysosome-associated protein transmembrane-4 (LAPTM4B) in human osteosarcoma tissue samples collected in our hospital, and to explore the possible correlations between the clinical pathological features of osteosarcoma patients and LAPTM4B expression.

Methods: Immunohistochemical (IHC) assays were performed to detect the expression levels of LAPTM4B in 62 tissue samples of osteosarcoma tissues and corresponding non-tumor tissues. According to LAPTM4B staining intensity in tumor tissues, osteosarcoma patients were classified into LAPTM4B high expression and low expression groups. In addition, the potential correlations between LAPTM4B expression levels and clinical pathological features were evaluated. In addition, we detected the effects of LAPTM4B on the proliferation and invasion of osteosarcoma cells through colony formation assay and transwell assay, respectively. We further explored the potential effects of LAPTM4B on tumor growth and metastasis using in vivo animal model.

Results: We revealed that LAPTM4B was highly expressed in human osteosarcoma tissues. We determined the significance between LAPTM4B and clinical features, including the tumor size (P = 0.004*) and the clinical stage (P = 0.035*) of osteosarcoma patients. Our results further demonstrated that ablation of LAPTM4B obviously blocked the proliferation and invasion of osteosarcoma cells in vitro and restrained tumor growth and metastasis in mice.

Conclusion: We investigated the potential involvement of LAPTM4B in osteosarcoma progression and confirmed LAPTM4B as a novel therapeutic target for osteosarcoma.

Key words: Invasion; LAPTM4B; Osteosarcoma; Proliferation; Therapeutic target

Introduction

Osteosarcoma (OC) is a common type of malignancy that originates in the bone, with high morbidity; it is the second leading cause of cancer-related death among young people¹,². Over the past 30 years, the combination of surgical resection and chemotherapy has been the most common treatment for advanced OC and has improved the 5-year total survival rate of OC patients to approximately 70%³-⁵. However, due to chemotherapy resistance, nearly 40% of OC patients experience recurrence or metastases, which results in poor prognosis⁶,⁷. Recently, targeted therapy became a promising therapeutic method for osteosarcoma, and multiple molecular targets have been identified, such as MYC or EGFR⁸,⁹. To combat this malignancy more effectively, the development of additional therapeutic targets is urgently needed.

Lysosome-associated protein transmembrane-4 (LAPTM4B), which contains a lysosome localization motif

Address for correspondence Xu-guo Sun, The School of Medical Laboratory, Tianjin Medical University, No. 22, Qixiangtai Road, Heping district, Tianjin, China 300070 Tel: 86-02223300609; Fax: 86-02223300609; Email: sunxuguo@tmu.edu.cn

Grant Sources: This work was supported by the Natural Science Foundation of Tianjin (16JCJYJC17800) and the National Natural Science Foundation of China (31600761 and 61703304).

Disclosure: The authors declare that they have no competing interests.

Received 6 March 2020; accepted 3 April 2020

Orthopaedic Surgery 2020;12:1253-1260 • DOI: 10.1111/os.12692

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
and localizes on late lysosomes, is known as a member of the LAPTM family and is widely expressed in multiple human tissues. LAPTM4B was first cloned in human hepatocellular carcinoma (HCC) tissues in 2000 and could regulate autophagy and lysosome function. In addition, a previous study showed that LAPTM4B contributes to late endosomal ceramide export to regulate cell death pathways. Another study demonstrated that LAPTM4B could activate the mTORC1 pathway through recruiting the LAT1-4F2hc Leu transporter to lysosomes.

The roles of LAPTM4B in the progression of multiple cancers has been widely discussed in the literature. LAPTM4B is overexpressed in several tumors, such as HCC, bladder cancer, and ovarian cancer. Multiple studies have confirmed that LAPTM4B can affect cell proliferation, invasion, apoptosis, and autophagy of several types of cancer cells. LAPTM4B contributes to HCC growth and metastasis, which is regulated by AP4. In breast cancer, LAPTM4B could predict lymph node metastasis and induce the aggressiveness of breast cancer cells. Although LAPTM4B plays an important role in a variety of tumors, its potential effects on OC remains unclear. We assume that LAPTM4B plays an important role in the progression of OC.

Interestingly, we found high expression levels of LAPTM4B in human osteosarcoma tissues and explored the potential correlations between LAPTM4B expression levels and clinical pathological characteristics (tumor size and clinical stage) of patients with osteosarcoma. We therefore found that LAPTM4B ablation remarkably blocked osteosarcoma cell proliferation and invasion and restrained tumor growth and metastasis in mice. LAPTM4B could, therefore, provide a novel and promising therapeutic target for osteosarcoma.

Materials and Methods

Antibodies and Primers
The antibodies used were: rabbit anti-LAPTM4B (1:200 dilution for immunohistochemistry [IHC]; 1:1000 dilution for immunoblot, PA5-43047, Thermo Fisher, Waltham, MA, USA) and mice anti-β-actin (1:2000 dilution, ab8227, Abcam, Cambridge, UK).

The quantitative polymerase chain reaction (PCR) primer sequences of LAPTM4B are as follows: forward, 5'-TGAACCTGGAGGTGACTTTGAG-3' and reverse, 5'-CAACAGTTGCCCGCTTTTAC-3'; The quantitative PCR primer sequences of GAPDH are as follows: 5'-CGA CACACTTGTCAGGCT-3' and reverse, 5'-GGTTGAGCACAGGTTACTTATT-3'.

Short hairpin RNA (shRNA) plasmids (Ready-to-package AAV) targeted LAPTM4B were bought from Addgene (Watertown, MA, USA). The targeted sequences of the LAPTM4B shRNA plasmids were as follows: sense, 5'-GGTGCGCCTTCGGAGCGAAGGTA-3'.

Immunohistochemistry
Tumor tissues were all collected from OC patients recruited in our hospital. To examine LAPTM4B expression in human osteosarcoma tissues, we conducted IHC assays. In brief, tumor or adjacent tissue sections were fixed with 4% paraformaldehyde (PFA) for 30 min at room temperature and subsequently blocked with 2% BSA for 20 min. Sections were then incubated with LAPTM4B antibodies at room temperature for 2 h. Subsequently, the sections were incubated with horseradish peroxidase (HRP) secondary antibody for 1.5 h, and diaminobenzidine was used as a chromogen substrate.

The expression level of LAPTM4B was scored as follows: staining intensity 0 = negative, 1 = low, 2 = modest, and 3 = high; and the proportion of stained cells 0 = 0% stained cells, 1 = 1%–30% stained cells, 2 = 31%–60% stained cells, and 3 = 61%–100% stained cells. A comprehensive score (score of staining intensity × score of stained cells percentage) <2 was considered negative staining, 2–3 low staining and >4 high staining. The sections of each patient were photographed within five visual fields, and two pathologists analyzed the sections.

Cell Culture and Transfection
Human osteosarcoma cell lines: MG-63 and U-2 OS were bought from the ATCC, and maintained in EMEM and MMM (McCoy’s 5a Medium Modified) culture medium, respectively, supplemented with 10% of fetal bovine serum at 37°C in a 5% CO2 incubator.

The shRNA plasmids were transfected into osteosarcoma cells using Lipofectamine 2000 (11668019, Invitrogen, CA, USA) according to the brochures. Stable knockdown clones were screened by lentivirus infection and used for the in vivo assays.

Quantitative Polymerase Chain Reaction Assay
TRIzol (15596026, Invitrogen, CA, USA) was used to extract total RNA from tumor cells. Subsequently, the RNA was reverse-transcribed by reverse transcriptase (M1701, Promega, Wisconsin, USA) to produce cDNA. Quantitative PCR was performed using a SYBR Ex Taq kit (638319, Takara, Japan), and the expression levels of LAPTM4B were normalized to the expression of GAPDH.

Immunoblot Assays
The cancer cells or tissues were lysed by RIPA Buffer (9800, Cell Signaling, Danvers, MA). Then the total proteins were separated through SDS-PAGE assays. The polyvinylidene fluoride (PVDF) membranes were blocked with 5% fat-free milk in TBST buffer and incubated with the primary antibodies for the detection of LAPTM4B and β-actin at room temperature for 2 h. Then the PVDF membranes were washed with TBST four times and the PVDF membranes were incubated with HRP-conjugate secondary antibodies for 45 min. After washing, each blot was detected using an ECL kit. To analyze the intensity of each band, ImageJ software was used.
Colony Formation Assay
A total of 1000 MG-63 or U-2 OS cells were seeded into a six-well culture plate and transfected with control or LAPTM4B shRNA plasmids and maintained in a 37°C, 5% CO2 incubator for 24 h. After 2 weeks, cells were fixed with PFA for 20 min at room temperature, subsequently stained with 0.2% crystal violet for 20 min, and washed with phosphate-buffered saline twice. Then the colony numbers were manually counted.

Transwell Assay
Both MG-63 and U-2 OS cells were transfected with control or LAPTM4B shRNA plasmids for 48 h and then resuspended in serum-free medium. The upper chambers of filters (8.0 μm membrane pores) were filled with 20% Matrigel in serum-free medium and incubated at 37°C for 30 min. Approximately 10^5 cells in 150 μL of medium were then seeded into the upper chambers of the inserts and induced to migrate toward the bottom chambers containing complete medium. After 24 h incubation, cells in the top chamber were removed using cotton swabs, and remaining cells were fixed with 4% PFA for 25 min and stained with 0.2% crystal violet for 20 min. Then the cell number was manually counted.

Tumor Growth Assay
All in vivo assay processes were approved by our Institutional Animal Care and Use Committee. Briefly, MG-63 cells were stably infected with control or LAPTM4B shRNA lentivirus. After infection for 48 h, approximately 5 × 10^5 control or LAPTM4B-depleted MG-63 cells were subcutaneously implanted into athymic nude mice. After 2 weeks, mice were examined for tumors. The volume of each tumor was photographed and measured.

Tumor Metastasis Assay
MG-63 cells were infected with control or LAPTM4B shRNA lentivirus to stably knock down its expression. After 48 h, nearly 5 × 10^5 infected cells were implanted into the tail vein of athymic nude mice. After 7 weeks, all metastasis tumor tissues were isolated from each group and photographed, and the metastasis degree was calculated and compared.

Statistics
GraphPad 5.0 software was used in this study for statistical analysis. All data were represented as mean ± standard deviation (SD). The correlation between clinical pathological characteristics and protein levels were analyzed by χ^2 analysis. Student’s t-test was used for statistical comparisons. * indicates P < 0.05 and statistical significance.

Results
LAPTM4B is Enhanced in Human Osteosarcoma Tissues and Associated with the Clinico-Pathological Features
To assess the possible involvement of LAPTM4B in the progression of osteosarcoma, 62 osteosarcoma tissue and the corresponding adjacent surgery samples were used to detect the expression of LAPTM4B by immunohistochemistry (IHC) assay. Notably, we found that LAPTM4B was mainly located in the cytoplasm of tumor cells and highly expressed in osteosarcoma tissues compared with adjacent non-tumor tissues (Fig. 1A,B). Subsequently, tumor tissue samples were classified into two groups, LAPTM4B high-expression and low-expression groups, according to the staining intensity of LAPTM4B (Fig. 1A,B). We noticed that high expression of

Fig. 1 LAPTM4B was obviously highly expressed in osteosarcoma tissues from patients. (A) Immunohistochemistry (IHC) revealed LAPTM4B expression levels in osteosarcoma tissues and the representative images are exhibited (100x and 400x magnification, respectively). (B) IHC assays exhibited LAPTM4B expression levels in corresponding adjacent tissues and the representative images are shown (100x and 400x magnification, respectively).
TABLE 1 Relationships of LAPTM4B and clinicopathological characteristics in 66 patients with osteosarcoma

| Feature           | All n = 66 | Low n = 22 | High n = 40 | $\chi^2$ | P     |
|-------------------|------------|------------|-------------|---------|-------|
| Age (year)        |            |            |             |         |       |
| <25               | 28         | 12         | 16          | 1.213   | 0.271 |
| ≥25               | 34         | 10         | 24          |         |       |
| Gender            |            |            |             |         |       |
| Male              | 35         | 16         | 19          |         |       |
| Female            | 27         | 6          | 21          |         |       |
| Tumor size        |            |            |             |         |       |
| <5 cm             | 27         | 15         | 12          | 8.417   | 0.004*|
| ≥5 cm             | 35         | 7          | 28          |         |       |
| Differentiation   |            |            |             |         |       |
| Low               | 24         | 11         | 13          | 1.832   | 0.176 |
| High              | 38         | 11         | 27          |         |       |
| Clinical stage    |            |            |             |         |       |
| I–II              | 40         | 18         | 22          | 4.459   | 0.035*|
| III               | 22         | 4          | 18          |         |       |

Fig. 2 The expression levels of LAPTM4B were obviously decreased in both MG-63 and U-2 OS cells after the transfection of LAPTM4B-targeted shRNA plasmids. (A) The results of quantitative PCR assays showed the obviously reduced expression levels of LAPTM4B in its short hairpin RNA (shRNA) plasmid-transfected MG-63 and U-2 OS cells, respectively. (B) Immunoblot assays revealed the efficient decrease of LAPTM4B expression levels after the transfection of its shRNA plasmids in both MG-63 and U-2 OS cells. Results are presented as mean ± SD, *P < 0.05.
LAPTM4B was detected in 40/62 (64.5%) cases, while low expression of LAPTM4B accounted for 35.5% cases.

We then compared the significance of clinicopathological features between low and high expression LAPTM4B groups. The clinical features, such as patient age, patient gender, and differentiation, were recorded and analyzed, with the P-values of 0.271, 0.055 and 0.176, respectively, suggesting no significance between low-expression and high-expression LAPTM4B groups in these features (Table 1). However, we found that the expression levels of LAPTM4B in tumor tissues was obviously correlated with tumor size and clinical stage, with the P-values of 0.004* and 0.035*, respectively, suggesting a significant correlation between LAPTM4B expression and these clinical features.

In summary, we demonstrated that LAPTM4B was highly expressed in osteosarcoma tissues and correlated with the clinical pathological features.

Knockdown of LAPTM4B Obviously Restrained the Proliferation and Invasion of Osteosarcoma Cells in vitro

To further evaluate the potential involvement of LAPTM4B in osteosarcoma development, the expression of LAPTM4B was depleted by the transfection of its shRNA plasmids in two types of osteosarcoma cell lines: MG-63 and U-2 OS, respectively. The silence efficiency of LAPTM4B shRNA in these two types of cells was measured through quantitative PCR and western blot assays, respectively. Results indicated that the transfection of LAPTM4B shRNA plasmids obviously decreased the expression levels of LAPTM4B in MG-63 and U-2 OS cells (Fig. 2A,B).

We then explored the effects of LAPTM4B on osteosarcoma cell proliferation through colony formation assays. Notably, we found that the proliferation capacity was significantly blocked by LAPTM4B depletion, with obviously decreased cell numbers. (Fig. 3A).

Tumor cell invasion is required for cancer metastasis. Therefore, we sequentially detected the effects of LAPTM4B ablation on the invasion of osteosarcoma cells through transwell assays. Interestingly, MG-63 and U-2 OS cells exhibited a marked low invasive capacity through the Matrigel-coated membranes when transfected with LAPTM4B shRNA plasmids, with significantly decreased cell numbers (Fig. 3B).

Therefore, these data revealed that LAPTM4B depletion dramatically suppressed cell proliferation and invasion of osteosarcoma cells in vitro.
LAPTM4B Facilitates Tumor Growth and Metastasis of Osteosarcoma Cells in Mice

As we previously found, LAPTM4B affected the proliferation and invasion of osteosarcoma cells in vivo. To further explore the possible role of LAPTM4B in the progression of osteosarcoma, in vivo tumor growth and metastasis assays were performed.

To detect tumor growth in vivo, MG-63 cells were infected with control or LAPTM4B shRNA lentivirus for 48 h to stably deplete the expression of LAPTM4B, and subsequently injected into nude mice. After 2 weeks, tumors were formed and the volume of tumors in different groups was measured each week. Representative tumor images were photographed and are shown in Fig. 4A. Based on the images and tumor growth curves, we noticed that the tumor volume in the LAPTM4B ablation group was markedly smaller than that in the control group, (Fig. 4A). We further performed lung metastasis assays in mice to detect the effects of LAPTM4B on tumor metastasis. The results confirmed that the incidence of lung metastasis for LAPTM4B depletion MG-63 cells was significantly decreased compared with the control (Fig. 4B). Then we detected the expression levels of LAPTM4B in tumor tissues from mice, and western blot assays showed that the expression of LAPTM4B in knockdown groups was obviously reduced compared with the control (Fig. 4C). In conclusion, all these results confirmed that LAPTM4B has a critical role in the growth and metastasis of osteosarcoma.

Discussion

Due to its fast growth and early metastasis, osteosarcoma has a high mortality rate among young people. Up to now, the pathogenesis and tumor driver genes of osteosarcoma have not been clarified, and the main treatment for osteosarcoma is surgery, chemotherapy, and adjuvant chemotherapy. However, 40% of patients with osteosarcoma are at risk of pulmonary metastasis and recurrence, with a 5-year survival rate of only 20%. Therefore, target therapy is a promising clinical treatment for osteosarcoma. Notably,
LAPTM4B IS A NOVEL THERAPEUTIC TARGET FOR OSTEOSARCOMA TREATMENT

we here identified that a member of the LAPTM family, LAPTM4B, has the potential to become a therapeutic target for osteosarcoma. We found high expression of LAPTM4B in 62 human osteosarcoma tissues. Moreover, our data revealed that LAPTM4B expression was markedly associated with the clinical-pathological features, including tumor size ($P = 0.004^*$) and clinical stage ($P = 0.035^*$), of patients with osteosarcoma.

Performing colony formation assays, we found that the proliferation of osteosarcoma cells was dramatically inhibited as a result of LAPTM4B shRNA transfection. Similarly, LAPTM4B knockdown suppressed the proliferation of lung adenocarcinoma cells through the PI3K/AKT signal pathway26. In hepatocellular carcinoma (HCC), LAPTM4B also facilitates cell proliferation and tumor growth via AKT signaling pathways28. We therefore hypothesize that LAPTM4B regulates osteosarcoma cell proliferation in a similar way. Our data further confirmed through transwell assays and lung metastasis assays, respectively, that LAPTM4B regulated cell invasion and tumor metastasis of osteosarcoma. In breast cancer and HCC, LAPTM4B also contributes to tumor metastasis and cell aggressiveness, and is associated with clinical features such as lymph node metastasis21,27. Previous studies have also indicated that the high expression of LAPTM4B is a risk factor for recurrence and is associated with poor prognosis in non-small-cell lung cancer16,28. In addition, the ablation of LAPTM4B suppressed the proliferation, invasion, and angiogenesis of HeLa cells29. LAPTM4B could activate the EGFR signal pathway to promote the development of gastric cancer, which was repressed by Beclin130. These studies, together with our findings, suggested LAPTM4B as a novel and promising therapeutic target for the treatment of multiple cancers. In addition to its regulatory function in a variety of tumors, LAPTM4B also has several important physiological functions in non-tumor cells. LAPTM4B mediates amino acid transporter interaction and late endosomal ceramide export, and hence regulates cell death pathways14,31. In addition, LAPTM4B could lead to uptake of Leu into lysosomes and activate the mTORC1 through recruiting LAT1-4F2hc to lysosomes15. We found that LAPTM4B was correlated with the clinical features and could promote the progression of osteosarcoma, although the mechanism remains unclear. Given the complexity of the LAPTM4B function, we should next explore whether LAPTM4B could regulate osteosarcoma development in a different manner, such as a lysosome-dependent manner.

Conclusion

We here revealed the high expression of LAPTM4B in human osteosarcoma tissues, and its expression level was obviously correlated with the clinical pathological features (including tumor size and clinical stage) of patients who underwent osteosarcoma. Ablation of LAPTM4B led to the inhibition of cell proliferation and invasion in vitro. In addition, LAPTM4B facilitates the growth and metastasis of osteosarcoma cells in mice. These findings therefore suggest LAPTM4B as a novel and promising therapeutic target for osteosarcoma in the future.

Acknowledgments

Not applicable.

References

1. Somers GR, Ho M, Ziehlenska M, Squire JA, Thornor PS. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol, 2005, 8: 525–532.
2. Murahari S, Jalkanen AL, Kulp SK, et al. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. BMC Cancer, 2016, 17: 67.
3. Yang Q, Yuan Q, Li H, et al. miR-223/Hsp70/JNK/JUN/miR-223 feedback loop modulates the chemoresistance of osteosarcoma cells by AKT-mediated signaling pathways. Biochem Biophys Res Commun, 2018, 497: 827–834.
4. Zheng K, Xu M, Wang L, et al. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: a single-center observational study. Medicine (Baltimore), 2018, 97: e11734.
5. Li W, Zhang S. Survival of patients with primary osteosarcoma and lung metastases. J BUON, 2018, 23: 1500–1504.
6. QI XT, LI YL, Zhang YQ, et al. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol Sin, 2019, 40: 546–555.
7. Xie L, Guo W, Li Y, Ji T, Sun X. Pathologic fracture does not influence local recurrence and survival in high-grade kidney osteosarcoma with adequate surgical margins. J Surg Oncol, 2012, 106: 820–825.
8. Zhou W, Hao M, Du X, et al. Advances in targeted therapy for osteosarcoma. Discov Med, 2014, 17: 301–307.
9. Diao C, Xi Y, Xiao T. Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett, 2018, 15: 2789–2794.
10. Ndiaye K, Carriere PD, Sirosio J, et al. Differential expression of lysosome-associated protein transmembrane-4 beta (LAPTM4B) in granulosa cells of ovarian follicles and in other bovine tissues. J Ovarian Res, 2015, 8: 12.
11. Zhang H, Tian B, Yu H, Yao H, Gao Z. LAPTM4B-35 protein as a potential therapeutic target in gastric cancer. Tumour Biol, 2014, 35: 12737–12742.
12. Zhou L, He XD, Chen J, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer, 2007, 43: 809–815.
13. Li Y, Zhang Q, Tian R, et al. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res, 2011, 71: 7481–7489.
14. Blom T, Li S, Dichtberger A, et al. LAPTM4B facilitates late endosomal ceramide export to control cell death pathways. Nat Chem Biol, 2015, 11: 799–806.
15. Milkereit R, Persaud A, Vanoaica L, Guetg A, Verrey F, Rotin D. LAPTM4B recruits the LAT1-4F2hc Leu transporter to lysosomes and promotes mTORC1 activation. Nat Commun, 2015, 6: 7250.
16. Kong F, Gao F, Chen J, et al. Overexpression of LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer. Oncotarget, 2016, 7: 56193–56199.
17. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol, 2010, 136: 275–281.
18. Yang Y, Xu J, Zhang Q. Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B. Onco Lett, 2018, 15: 7923–7933.
19. Yin M, Li C, Li X, et al. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol, 2011, 104: 29–36.
20. Meng Y, Wang L, Xu J, Zhang Q. AP4 positively regulates LAPTM4B to promote hepatocellular carcinoma growth and metastasis, while reducing chemotherapy sensitivity. Mol Oncol, 2018, 12: 373–390.
21. Xiao M, Yang S, Meng F, et al. LAPTM4B predicts axillary lymph node metastasis in breast cancer and promotes breast cancer cell aggressiveness in vitro. Cell Physiol Biochem, 2017, 41: 1072–1082.
22. Rickerl K, Fang F, Tao J. Molecular genetics of osteosarcoma. Bone, 2017, 102: 69–79.
23. Wang JY, Wu PK, Chen PC, et al. Manipulation therapy prior to diagnosis induced primary osteosarcoma metastasis—from clinical to basic research. PLoS One, 2014, 9: e96571.
24. Zou Q, Xiao X, Liang Y, et al. miR-19a-mediated downregulation of RhoB inhibits the dephosphorylation of AKT1 and induces osteosarcoma cell metastasis. Cancer Lett, 2018, 428: 147–159.
25. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol, 2013, 25: 398–406.
26. Wang L, Meng Y, Zhang QY. LAPTM4B is a novel diagnostic and prognostic marker for lung adenocarcinoma and associated with mutant EGFR. BMC Cancer, 2019, 19: 293.
27. Li S, Wang L, Meng Y, Chang Y, Xu J, Zhang Q. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients. Oncotarget, 2017, 8: 41282–41293.
28. Tang H, Tian H, Yue W, et al. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer. Med Oncol, 2014, 31: 974.
29. Meng F, Chen X, Song H, Lou G. LAPTM4B down regulation inhibits the proliferation, invasion and angiogenesis of HeLa cells in vitro. Cell Physiol Biochem, 2015, 37: 890–900.
30. Tian M, Chen Y, Tian D, Qiao X, Ma Z, Li J. Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells. Gene, 2017, 626: 48–53.
31. Zhou K, Dichilberger A, Martinez-Seara H, et al. A ceramide-regulated element in the late Endosomal protein LAPTM4B controls amino acid transporter interaction. ACS Cent Sci, 2018, 4: 548–558.